Skip to Content
Merck
  • Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives.

Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives.

European journal of medicinal chemistry (2012-01-28)
Daniel B Nichols, Guy Fournet, K R Gurukumar, Amartya Basu, Jin-Ching Lee, Naoya Sakamoto, Frank Kozielski, Ira Musmuca, Benoît Joseph, Rino Ragno, Neerja Kaushik-Basu
ABSTRACT

Structure-based studies led to the identification of a constrained derivative of S-trityl-l-cysteine (STLC) scaffold as a candidate inhibitor of hepatitis C virus (HCV) NS5B polymerase. A panel of STLC derivatives were synthesized and investigated for their activity against HCV NS5B. Three STLC derivatives, 9, F-3070, and F-3065, were identified as modest HCV NS5B inhibitors with IC(50) values between 22.3 and 39.7 μM. F-3070 and F-3065 displayed potent inhibition of intracellular NS5B activity in the BHK-NS5B-FRLuc reporter and also inhibited HCV RNA replication in the Huh7/Rep-Feo1b reporter system. Binding mode investigations suggested that the STLC scaffold can be used to develop new NS5B inhibitors by further chemical modification at one of the trityl phenyl group.